id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1446657,0a00a669-c734-4cd8-ae0e-ecae7edbe8e0,Q3,"ALFRED W. CORS, JR",285277,RETIRESAFE,2013,third_quarter,CSP,"Support Automative ""Right to Repair"" legislation and/or regulation.
Support the ""Promoting Automotive Repair, Trade, and Sales (PARTS) Act,"" H.R. 1663 and S. 780.","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),President of the U.S.,SENATE",5060,,0,0,2013-10-17T12:51:35.630000-04:00
1446658,0a00a669-c734-4cd8-ae0e-ecae7edbe8e0,Q3,"ALFRED W. CORS, JR",285277,RETIRESAFE,2013,third_quarter,MMM,"Support H.R. 351 and S.351 to repeal the Medicare Independent Payment Advisory Board mandated by the Affordable Care Act
Oppose any reduction of Medicare Part B drug and biologic reimbursement payments that will harm patients.
Support robust Part D formularies and continued coverage of the six protected classes.
Support raising the Part D specialty tier cost-sharing threshold above the $600 minimum, and to at least index it to inflation.Support strong Part D oversight and improved transparency for consumers, as well as a better process for notice of non-coverage, for appeals, and exceptions to provide the best access to necessary, life-saving prescription medications.
Support changes to the Part D Program that would address gaps in coverage, eliminate onerous cost-shifting through the use of specialty tiers and restrictive utilization management tools. Support any changes that improve the effectiveness of the program for those receiving low income subsidies. 
Support the most stringent safety requirements for any substitution of biosimilar drugs for any prescribed biologic, including notification of both the patient and the prescribing physician.
Oppose any cuts to the Medicare Part D Program or any legislation requiring the Secretary of Health and Human Services to ""negotiate"" Part D prices or rebates that will forever limit access to the best drugs and biologics for Medicare beneficiaries. 
Support ""Fight Fraud First"" efforts (rather than Medicare benefit cuts or fee increases) to reduce overall Medicare spending.
Oppose any changes to the Medicare Part D program that would shift additional costs to beneficiaries or create barriers to access, both of which actions would lead to cost increases in other parts of the Medicare program.
Oppose all proposed cuts to Medicare reimbursements rates for critical home health services under the Home Health Prospective Payment System (HHPPS).

Support the ""Part D Beneficiary Appeals Fairness Act,"" H.R. 2827 and S. 1365.","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),President of the U.S.,SENATE",5060,,0,0,2013-10-17T12:51:35.630000-04:00
1446659,0a00a669-c734-4cd8-ae0e-ecae7edbe8e0,Q3,"ALFRED W. CORS, JR",285277,RETIRESAFE,2013,third_quarter,HCR,"Commented to the Secretary of Health and Human Services on the Proposed Rule ""Medicaid, Children's Health Insurance Programs, and Exchanges: Essential Health Benefits in Alternative Benefit plans, Eligibility Notices Appeals and Other provisions Related to Eligibility and Enrollment for Exchanges, Medicaid and CHIP, and Medicaid Premiums and Cost Sharing."" Support language that states must cover all drugs by companies that participate in the Medicaid drug rebate program. Oppose language that allows states toplace ""limitations on amount, duration, and scope"" and ""adopt prior authorization other utilization control measures, as well as policies that promote the use of generic drugs,"" as open-ended limitations that can greatly impact access and violate the non-discrimination requirements included in the ACA. Urged at least 60 days for the public to review and comment on the respective state plans and subsequent plan changes. Support requiring all Alternative Benefit Plans to cover all preventive service that plans in the marketplace must cover, and oppose cost sharing for the Medicaid expansion population. Urge HHS to ensure that ""medically frail"" beneficiaries are not forced into a plan that provides fewer benefits than the ABP or the traditional Medicaid package. Urge the strongest possible non-discrimination rule across plans. Oppose copays for the very poor, or in the alternative, support monthly caps on copays. Oppose discriminatory copays and cost-sharing for non-preferred drugs.
Oppose the use of ""cost-effectiveness standards"" which may compromise care. Support preferred cost-sharing on non-preferred drugs where the prescribing physician determines that the preferred drug would not be as effective or would have adverse effects for the patient. Urge clear and understandable notices and an easily understood, fully accessible, and speedy appeals process. 

Oppose sequestration budget cuts that negatively impact the Alzheimer's disease patient community including cuts to basic and translational Alzheimer's research at NIH, funding for FDA, and funding for federal programs that support individuals with dementia, family and paid caregivers at the Administration on Aging (AOA), the Health Resources and Services Administration (HRSA) and other agencies authorized under the Older Americans Act (OAA).

Supported all of the Leaders Engaged on Alzheimer's Disease (LEAD) Coalition's recommendations to improve the implementation of the National Plan to Address Alzheimer's Disease, as submitted by letter to the HHS Secretary.

Urged the HHS Secretary to appoint a new Agency for Healthcare Research and Quality (AHRQ) Director who is not only well-qualified, but also demonstrates ""a commitment to recognizing the diversity, perspective, and participation of patients in every decision the agency makes.""

Support FDA draft industry guidance regarding the development of drugs and biomarkers for the safe and effective early stage treatment of Alzheimer's Disease. 

Urged the Dept. of Labor to revise the Affordable Care Act (ACA) exception regarding the coordinated annual limitation on out-of-pocket maximums put forth in the February 2013 ""Frequently Asked Questions about the ACA"" that indicates a major disparity in annual out-of-pocket limits between patients. This is unfair and could cause major hardships for patients dealing with chronic health conditions where out-of-pocket spending can total thousands of dollars each year.

Supported the National Institutes of Health (NIH) creation of the National Center for Advancing Translation Sciences' (NCATS)
""Discovering New Therapeutic Uses for Existing Molecules Initiative,"" especially as it applies to the enhanced development of new treatments for Alzheimer's Disease.

Support the US Preventative Services Task Force (USPSTF) Transparency and Accountability Act of 2013, H.R. 2143.

Support the Drug Supply Chain Security Act, S.B. 959.

Support the Orphan Drug Tax Credit (ODTC).","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),President of the U.S.,SENATE",5060,,0,0,2013-10-17T12:51:35.630000-04:00
1446660,0a00a669-c734-4cd8-ae0e-ecae7edbe8e0,Q3,"ALFRED W. CORS, JR",285277,RETIRESAFE,2013,third_quarter,RET,"Oppose the use of any version of a ""chained"" consumer price index (CPI) for the calculation of Social Security and military retiree benefit cost of living adjustments or COLAs.
Support the CPI for Seniors Act, H.R. 2154.","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),President of the U.S.,SENATE",5060,,0,0,2013-10-17T12:51:35.630000-04:00